Keywords
2019 NCOV
pandemic
physiopathology
SARS
transmission
Abstract
The disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) or simply corona virus disease-2019 (COVID-19), has rapidly spread throughout the world. World Health Organization declared a global health emergency on January 30, 2020 announcing it as a Pandemic. The outbreak of the disease has posed serious health threat. A search was conducted for review which included various articles from 2019 to 2021 in PubMed/MEDLINE with keywords ACE2, 2019 NCOV, pandemic, physiopathology, SARS, Transmission. Both humoral and acquired immunity are targeted by the virus during progression of diseases. A cellular biology perceptive of pathogenesis is useful for framing clinical course of the diseases and its related complication. Knowledge of underlying pathophysiology regarding release of innate immune modulators such as CXCL10, beta and alpha interferons will facilitate the development of therapeutic modalities in future. Despite implementing all the preventive efforts SARS-CoV-2, exponential mode of infection rate is still existing with epidemic doubling time less than a week. In this review, an update on pathophysiology, cell biology of virus and immune modulation related to diseases are considered and has been described. Any of the mechanisms and assumptions discussed in the article and in our understanding of SARS-CoV-2 may be revised as further evidence emerges.
References
Woo PC. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alpha coronavirus and beta coronavirus and avian coronaviruses as the gene source of gamma coronavirus and delta coronavirus. J Virol. 2012; 86(7):3995-8.
Fong SJ, Li G, Dey N, Crespo RG, Herrera-Viedma E. Finding an accurate early forecasting model from small dataset: A case of 2019-ncov novel coronavirus outbreak. Int. J Interact Multimed. 2020;6(1)132-40
Ge, XY, Yang, WH, Zhou, JH. Detection of alpha- and betacoronaviruses in rodents from Yunnan, China. Virol J. 2017;98(14) 069-80
Zhou F, Yu T, Du R. . Lancet. 2020; 395(10229)1054-62.
Lu X, Zhang L, Du H, Zhang J, Li Y, Zhang W, et al. Chinese Pediatric Novel Coronavirus Study SARS-cov-2 infection in children. N Engl J Med. 2020;382(17)1663-65
Qiu H., Wu J., Hong L., Luo Y., Song Q., Chen D et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020; 3099(20):30198-5.
Jia H.P., Look D.C., Shi L., Hickey M., Pewe L., Netland J., et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol.2005;79(23):14614-21.
Nick bakhsh S., Mair C., Matthews L., Reeve R., Johnson P.C.D., Thorburn F. et al. Virus-virus interactions impact the population dynamics of influenza and the common cold. Proc Natl Acad Sci 2019; 116(52):27142-50.
Bosch B.J., van der Zee R., de Haan C.A., Rottier P.J. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003; 77(16):8801–11.
Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y et al. Analysis of therapeutic targets for SARS-cov-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766-78.
Cascella M, Rajnik M, Aleem A, Dulebohn S, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. 2021 Apr 20.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S et al. SARS-cov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-80.
Jaimes JA, Millet JK, Whittaker GR. Proteolytic cleavage of the SARS-cov-2 spike protein and the role of the novel S1/S2 site. I Science. 2020;23(6):1012-12.
Korber B, Fischer WM, Gnanakaran S .Tracking changes in SARS-cov-2 spike: evidence that D614 G increases infectivity of the covid-19virus. Cell 2020;182(812): 827.
Yan R, Zhang Y, Li Y, Xia L ,Guo Y, Zhou Q et al. Structural basis for the recognition of SARS-cov-2 by full-length human ACE2. Science 2020; 367(6485):1444-8.
Wrapp D, Wang N, Corbett KS. Cryo- EM structure of the 2019-n cov spike in the prefusion conformation. Science. 2020; 367(6483):
-63.
Wölfel R, Corman VM, Guggemos W. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465-69.
Cevik M, Tate M, Lloyd O, SARS-cov-2, SARS-cov-1 and MERS-cov viral load dynamics, duration of viral shedding and infectiousness: a living systematic review and meta-analysis. Lancet Microbe. 2020;2(1):13-22.
Meyerowitz E, Richterman A, Bogoch I, Low N, Cevik M. Towards an accurate and systematic characterization of persistently asymptomatic infection with SARS-cov-2. Lancet Infect Dis. 2020; 21(6):163-69.
Qiu X,Nergiz AI,Maraolo AE. Defining the role of asymptomatic SARS-CoV-2transmission: a living systematic review. MedRxiv [Preprint]2020.
Wan Y, Shang J, Graham R. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020; 94(7): 00127-20.
Hoffmann M, Kleine-Weber H, Schroeder S. SARS-cov-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; in press.
Sims AC, Baric RS, Yount B. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005;79(24):15511–524.
Wu Z, Mc Googan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. J Am Med Assoc. 2020;323(13):
-41.
Qian Z, Travanty EA, Oko L. Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus. Am J Respir Cell Mol Biol. 2013;48(6):742–48.
Wang J, Nikrad MP, Phang T. Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am J Respir Cell Mol Biol. 2011;45(3):582–91.
Mossel EC, Wang J, Jeffers S. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008; 372(1):127–135.
Weinheimer VK, Becher A, Tonnies M. Influenza. A viruses target type II pneumocytes in the human lung. J Infect Dis. 2012; 20(6): 1685–1694.
Kumar PA, Hu Y, Yamamoto Y. Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection. Cell. 2011; 147(3):525–38.
Yee M, Domm W, Gelein R. Alternative progenitor lineages regenerate the adult lung depleted of alveolar epithelial type 2 cells. Am J Respir Cell Mol Biol. 2017;56(4): 453-64.
Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007; 170(4):1136-47.
Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420–22.
Buitrago-Garcia D,Egli-Gany D,Counotte MJ.Occurrence and transmission potential of asymptomatic and presymptomaticSARS-CoV-2infections:aliving systematic review and meta-analysis. PloSMed. 2020; 17(9):10033-46.
Hui KPY, Cheung MC, Perera RAPM. Tropism, replication competence, and innate immune responses of the corona virus SARS-CoV-2 in human respiratory tract and conjunctiva: ananalysis in ex vivo and in-vitro cultures. Lancet Respir Med. 2020; 8(7):687-95.
Cevik M, Marcus J, Buckee C, Smith T. SARS-cov-2 transmission dynamics should inform policy. ClinInfecDis. 2020;73(2):170-176.
Klompas M,Baker MA,Rhee C. Airborne transmission of SARS-CoV-2: theoretical considerations and available evidence. J Am Med Assoc. 2020; 324(5):441-42.
Centers for Disease Control and Prevention. How COVID-19 spreads. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html.
Centers for Disease Control and Prevention.Scientific brief:SARS-CoV-2 and potential air borne transmission.2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-sars-cov2.html
Yu IT,Li Y,Wong TW. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med. 2004; 350(17)1731-39.
Chin A WH, Chu JTS, Perera MRA. Stability of sars-cov-2in different environmental conditions. Lancet Microbe. 2020; 107(1):105-07.
Van Doremalen N, Bushmaker T, Morris DH .Aerosol and surface stability of SARS-cov-2 as compared with SARS-cov-1. N Engl J Med. 2020; 382(16):1564-67.
Mangalmurti N,Hunter CA.Cytokine Storms :understanding COVID-19.Immunity. 2020;53(1):19-25.
Wu C,Chen X,Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with corona virus disease2019pneumonia in wuhan,China. JAMA Intern Med. 2020; 180(7):934-43.
Cevik M, Bamford CGG, Ho .Clin Microbiol Infect. 2020; 26(7):842-47.
Monteil V,Kwon H,Prado P. Inhibition of SARS-cov-2 infection s in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020; 181(4):905-13.
Varga Z,Flammer AJ,Steiger P, Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234):1417-18.
Wang C,Xie J,Zhao L. Alveolar macrophage dysfunction and cytokines to determin the pathogenesis of two severe COVID-19patients. EbioMedicine. 2020; 57:102833.
Liu PP,Blet A,Smyth D,Li H. The science underlying covid-19: implications for the cardiovascular system. Circulation. 2020; 142(1):68-78.
Carsana L, Sonzogni A, Nasr A. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020; 20(10):1135-40.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-cov-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Anti microb. Agents. 2020. 1;55 (3):105924.